Background Respiratory syncytial virus (RSV) causes substantial winter pressure on adult services. In the UK, RSV vaccination currently targets adults aged ≥75 years and care home residents; it ...

Respiratory infections are the leading causes of hospitalizations, ED visits and mortality in children in the United States ...

February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced ...

DOHA: The Ministry of Public Health (MoPH) has urged those most at risk to receive the Respiratory Syncytial Virus (RSV) Vaccine, which is currently available at HMC hospitals ...

Infectious disease experts are dismayed that the monoclonal antibody against respiratory syncytial virus (RSV) for infants, widely considered a crucial advance in public health, has been downgraded on ...

During the 2024-2025 respiratory syncytial virus (RSV) season in the US, maternal RSV vaccination and receipt of nirsevimab were effective against medically attended RSV-associated acute respiratory ...

As respiratory virus season intensifies, doctors are urging families across metro Atlanta and Georgia to take extra precautions as flu and RSV cases continue to climb among children, according to ...

RSV, or respiratory syncytial virus, is a common illness that causes infections of the breathing passages and lungs. North Carolina's RSV levels are currently classified as "very low," a significant ...

As families get ready to celebrate the holidays, people should be aware of the increased risk of sickness during celebrations. Health experts are warning Americans to expect a rise in winter ...

The flu, colds and other respiratory illnesses are often more common throughout the winter. People spend more time indoors together, especially during the holidays, which promotes the spread of ...

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems have been reported. The review covers Beyfortus (from Sanofi and AstraZeneca) ...

A significant percentage of U.S. adults have risk factors for severe RSV, yet vaccine uptake remains low, especially among eligible populations. Current RSV vaccine guidelines focus on older adults, ...